Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Universite Paris 13 - Paris Nord

Université Paris Diderot-paris 7

Université De Paris

Centre National De La Recherche Scientifique

Institut Pasteur

Universite Paris Cité

Université Paris Diderot

Balt Extrusion

Fondation a De Rothschild

Giuseppina Caligiuri

Antonino Nicoletti

Sylvie Bay

Dominique Le Guludec

Jonathan Vigne

Jean-Philippe Mickael Desilles

Mikael Mazighi

Disclosed is CD31for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31ligand in different rat models of inflammation indeed showed that CD31is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.

CD31as a molecular target for imaging of inflammation

The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.

CD31 peptides

The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.

Detection of platelet-derived shed CD31

The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.

CD31 peptides for the treatment of thrombotic or autoimmune disorders

The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.

Detection of shed CD31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways

CD31 peptides in the treatment of thrombotic and autoimmune disorders

Growing community of inventors

Paris, France

Giuseppina Caligiuri